Solum

248070 · KOSPI · Information Technology · SMALL CAP

Updated terms.

Solum updated the disclosed terms of a subsidiary's acquisition of Icure Pharmaceutical Incorporation, now worth US$12.8M.

M&A([Amended] Decision to acquire shares/equity in another company (voluntary) (subsidiary))· FILED 2026-08-13· RCEPT 20260813800129

US$12.8MDeal value
1.4%vs. company assets

Converted at 1 USD ≈ ₩1,416.85 (filing-date rate, 2026-08-13 close)

A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-08-14) →

What happened

Solum updated the disclosed terms of a subsidiary's acquisition of Icure Pharmaceutical Incorporation, now worth US$12.8M.

For context, this deal is worth about 1.4% of the company's consolidated total assets.

TargetIcure Pharmaceutical Incorporation
Deal valueUS$12.8M
vs. company assets1.4%
Filed2026-08-13, [Amended] Decision to acquire shares/equity in another company (voluntary) (subsidiary)
SourceDART rcept 20260813800129 → open original filing

Versions of this filing

  1. 2026-06-29Original
  2. 2026-08-05Amendment 1
  3. 2026-08-13Amendment 2 (this page)
  4. 2026-08-14Amendment 3

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-08-13 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.